Halozyme grants ENHANZE rights to Incyte for developing subcutaneous cancer therapy formulations, ai

Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Incyte (NASDAQ:INCY) with a Buy and

Bank of New York Mellon Corp lessened its holdings in Incyte Corporation (NASDAQ: INCY) by 1.3% duri

Fifth Third Bancorp boosted its stake in shares of Incyte Corporation (NASDAQ: INCY) by 145.2% in th

Andra AP fonden lessened its position in Incyte Corporation (NASDAQ: INCY) by 34.6% during the undef

Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today announ

Agreement provides Incyte the rights to develop and commercialize ENHANZE® with its mutCALR developm

Rapid oral presentations will highlight new Phase 1 data across Incyte’s solid tumor portfolioBoth I

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Data to Be Highlighted in Four Rapid Oral Presen

Barclays analyst Etzer Darout maintains Incyte (NASDAQ:INCY) with a Overweight and raises the pri

Incyte reports Phase 1/2 latarcibart data showing lower bleeding rates and favorable safety in patie

BMO Capital analyst Evan Seigerman maintains Incyte (NASDAQ:INCY) with a Market Perform and raise

RBC Capital analyst Brian Abrahams maintains Incyte (NASDAQ:INCY) with a Sector Perform and raise

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Incyte (NASDAQ:INCY) with a Buy and

UBS analyst Ashwani Verma maintains Incyte (NASDAQ:INCY) with a Neutral and raises the price targ

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment opt

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Incyte (NASDAQ:INCY) with a Buy and

Truist Securities analyst Srikripa Devarakonda maintains Incyte (NASDAQ:INCY) with a Hold and rai

Top Wall Street analysts changed outlook on top names. See all changes, including upgrades/downgrade

Top Wall Street analysts upgraded APA, INCY, COP, OVV, BWXT stocks with higher price targets. Check

BMO Capital analyst Evan Seigerman upgrades Incyte (NASDAQ:INCY) from Underperform to Market Perf

Phase 1 study of INCA33890 and muzastotug expected to begin in 2026 in 3L MSS CRC patients with and

Tech stocks hit new highs as the Nasdaq 100 rallies 0.7% midday. Investors eye a Fed rate cut, Trump

  On Monday, 369 companies set new 52-week lows.

  On Thursday, 148 companies set new 52-week lows.

  Thursday's session saw 189 companies set new 52-week lows.

Stocks That Hit 52-Week Lows On Wednesday

Stocks That Hit 52-Week Lows On Monday